Health (Drugs and Poisons) Regulation 1996

Drug Therapy Protocol – Pharmacist Vaccination Program

Queensland Government

Healthcare Approvals and Regulation Unit
Chief Medical Officer and Healthcare Regulation Branch
Queensland Health
PO Box 21
Fortitude Valley BC QLD 4006
Telephone (07) 3708 5264
Email: HARU@health.qld.gov.au

Disclaimer: Please note that any material printed is regarded as an uncontrolled copy. It is the responsibility of the person printing the document to refer frequently to http://www.health.qld.gov.au for updates.
I, Prof Scott Kitchener, Senior Medical Advisor, Chief Medical Officer and Healthcare Regulation Branch, pursuant to the Health (Drugs and Poisons) Regulation 1996, sections 171(2) & (5) and 257(2) & (3)(d) hereby certify this document as the Drug Therapy Protocol – Pharmacist Vaccination Program.

Conditions
1. A pharmacist or a trainee pharmacist under the direction and personal supervision of a pharmacist authorised to administer a vaccine under this Drug Therapy Protocol may administer a restricted drug or poison listed in Appendix 1, column 1 only:
   1.1 in the form of the drug or poison stated in Appendix 1, column 1 (if any);
   1.2 by a route of administration for the drug or poison stated in the current online edition of the Australian Immunisation Handbook\(^1\), or as stated in the product information approved by the Therapeutic Goods Administration (TGA); and
   1.3 subject to the restriction or condition for the drug or poison stated in Appendix 1, column 2.
2. The pharmacist or a trainee pharmacist under the direction and personal supervision of an authorised pharmacist must administer the restricted drug or poison in accordance with:
   2.1 the Queensland Health 'Queensland Pharmacist Vaccination Standard'; and
   2.2 the current edition of the Australian Immunisation Handbook.
3. Before administering a restricted drug or a poison, the pharmacist or a trainee pharmacist must be familiar with the contra-indication(s) and known side effects of the drug or poison and advise the patient accordingly.
4. If Consumer Medicines Information (CMI) is available for the medicine, the pharmacist must, where reasonably practicable, offer the information to each person to whom the pharmacist administers the drug.

Certification
Drug Therapy Protocol – Pharmacist Vaccination Program (QH-DTP-PVP-04:2020)

Certified at Brisbane on this 21st day of July 2020

Prof Scott Kitchener
Senior Medical Advisor
Department of Health

Notes:
(a) The pharmacist or a trainee pharmacist must be aware that practising within the Drug Therapy Protocol does not relieve that person of their legal responsibility or accountability for that person’s actions and may not provide immunity in case of negligence.
(b) All relevant provisions of the Health (Drugs and Poisons) Regulation 1996 apply

Appendix 1

Drug Therapy Protocol – Pharmacist Vaccination Program

<table>
<thead>
<tr>
<th>COLUMN 1</th>
<th>COLUMN 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RESTRICTED DRUG OR POISON</strong></td>
<td><strong>REstrictions/Conditions</strong></td>
</tr>
<tr>
<td>Influenza vaccine</td>
<td>Persons aged 10 years or over</td>
</tr>
<tr>
<td>Diphtheria-tetanus-acellular pertussis vaccine</td>
<td>Persons aged 16 years or over</td>
</tr>
<tr>
<td>Diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine</td>
<td>Persons aged 16 years or over</td>
</tr>
<tr>
<td>Measles-mumps-rubella vaccine</td>
<td>Persons aged 16 years or over</td>
</tr>
<tr>
<td>Cholera vaccine</td>
<td>Persons aged 16 years or over</td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em> type B vaccine</td>
<td>Persons aged 16 years or over</td>
</tr>
<tr>
<td>Hepatitis A vaccine</td>
<td>Persons aged 16 years or over</td>
</tr>
<tr>
<td>Meningococcal ACWY vaccine</td>
<td>Persons aged 10 years or over</td>
</tr>
<tr>
<td>Poliomyelitis vaccine</td>
<td>Persons aged 16 years or over</td>
</tr>
<tr>
<td>Pneumococcal vaccine</td>
<td>Persons aged 16 years or over</td>
</tr>
<tr>
<td>Adrenaline in a strength of 0.1% or less • in a preloaded device such as an autoinjector, or • in an ampoule</td>
<td>For use in treatment of anaphylaxis only</td>
</tr>
</tbody>
</table>